A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 6, 2010

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions

LeukopeniaNeutropeniaInfectionsWartsMyelokathexis

Interventions

DRUG

Mozobil (TM)

twice daily subcutaneous injection or via continuous subcutaneous infusion

Trial Locations (1)

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH